Efficacy and safety of rituximab in anti-synthetase antibody positive and negative subjects with idiopathic inflammatory myopathy: a registry-based study
Author:
Affiliation:
1. Division of Rheumatology, Department of Medicine, Solna, and Center for Molecular Medicine, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
2. Division of Rheumatology, Jewish General Hospital, Montreal, Quebec, Canada
Funder
Visithan-Khy Award
Jewish General Hospital Department of Medicine Foundation Fund
Swedish Research Council
Swedish Rheumatism Association
King Gustaf V 80-year Foundation
Rheumatism Association
King Gustaf V’s and Queen Victoriás Frimurarstiftelse
Regional Agreement on Medical Training and Clinical Research
Stockholm County Council and Karolinska Institutet
Publisher
Oxford University Press (OUP)
Subject
Pharmacology (medical),Rheumatology
Link
http://academic.oup.com/rheumatology/article-pdf/58/7/1214/28852852/key450.pdf
Reference23 articles.
1. Testing for myositis specific autoantibodies: comparison between line blot and immunoprecipitation assays in 57 myositis sera;Cavazzana;J Immunol Methods,2016
2. Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay;Ghirardello;Rheumatology,2010
3. Advances in serological diagnostics of inflammatory myopathies;Benveniste;Curr Opin Neurol,2016
4. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis;Gordon;Cochrane Database Syst Rev,2012
5. Current perspective on rituximab in rheumatic diseases;Schioppo;Drug Des Devel Ther,2017
Cited by 24 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Effectiveness and safety of low dose Rituximab as remission-maintenance treatment for patients with refractory idiopathic inflammatory myopathies: results of a retrospective study from a monocentric cohort;Clinical Rheumatology;2024-08-28
2. Novel B-cell subsets as potential biomarkers in idiopathic inflammatory myopathies: insights into disease pathogenesis and disease activity;Journal of Leukocyte Biology;2024-03-30
3. Long-lasting improvement of refractory antisynthetase syndrome with tocilizumab: a report of two cases;RMD Open;2023-12
4. B cell repopulation trajectory after rituximab treatment in autoimmune diseases: a longitudinal observational study;Clinical and Experimental Medicine;2023-09-26
5. Healthcare utilization and unmet needs of patients with antisynthetase syndrome: An international patient survey;Rheumatology International;2023-07-15
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3